Pre-order Enquiry
Request Free Sample
Global Human Albumin Market Research Report 2021
SKU ID : QYR-17222404 | Publishing Date : 20-Jan-2021 | No. of pages : 99
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
Human albumin was initially used only as a volume replacement therapy; however, extensive research has shown that human albumin has numerous applications in other therapeutic areas as well. For instance, Grifols is exploring the use of the product to stabilize Alzheimer’s disease. Moreover, drugs containing human serum albumin, such as Levemir and Abraxane are used to treat diabetes and metastatic breast cancer, respectively. Furthermore, the on-going research and augmented adoption of albumin in the new therapeutic areas will boost this market’s growth during the predicted period.
The global Human Albumin market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Human Albumin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Human Albumin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Human Albumin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
5% Concentrations
25% Concentrations
Others
Segment by Application
Therapeutics
Drug Formulation & Vaccine
Component of Media
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Human albumin was initially used only as a volume replacement therapy; however, extensive research has shown that human albumin has numerous applications in other therapeutic areas as well. For instance, Grifols is exploring the use of the product to stabilize Alzheimer’s disease. Moreover, drugs containing human serum albumin, such as Levemir and Abraxane are used to treat diabetes and metastatic breast cancer, respectively. Furthermore, the on-going research and augmented adoption of albumin in the new therapeutic areas will boost this market’s growth during the predicted period.
The global Human Albumin market was valued at US$ XX million in 2019 and is expected to reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
This report focuses on Human Albumin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Human Albumin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Human Albumin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
5% Concentrations
25% Concentrations
Others
Segment by Application
Therapeutics
Drug Formulation & Vaccine
Component of Media
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
CSL Behring
Grifols
Baxalta
Octapharma
Kedrion
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
